Techson IP Announces Exclusive Partnership Agreement with Bright Green Corporation

Share Article

Techson’s Cannabis Intellectual Property Advisory practice will deliver strategic intellectual property acquisition and consulting services to Bright Green as it prepares to scale its operations

Techson IP (“Techson”), a patent and intellectual property strategy consulting firm, and Bright Green Corporation (BGXX) (“Bright Green”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell legally under federal and state laws cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced an exclusive partnership agreement to collaborate on the acquisition and future development of intellectual property (IP) across the cannabis industry. Techson will be the exclusive broker and will research, review and assess new IP available in the sector and being offered to Bright Green for acquisition or licensing. Additionally, Techson will provide its strategic innovation research and consulting services as Bright Green ramps up its grow operations and brings its world-class research and development facilities online. Terms of the agreement were not disclosed.

“Techson has been building out its patent advisory practice since 2019 by focusing on emerging industries where intellectual property development and procurement have traditionally taken a back seat to productization. Spring boarding off our success as a leading patent research consultancy, we are helping clients build strategic patent portfolios that are complementary to the anticipated growth and revenue ahead,” says CEO of Techson, Luke Barbin. “Cannabis has unprecedented potential, and we believe that Bright Green will have an edge on the competition because they are willing to commit significant resources now to build a longer-term technology vision for the cannabis industry. Techson has already secured dozens of cannabis patent families and will look to sign and deploy these innovations in market leaders like Bright Green.”

“Bright Green is focused on strategically expanding its reach to serve both pharmaceutical opportunities as well as cannabis medical research product development on an unprecedented scale,” said Bright Green’s CEO, Ed Robinson. “As we accelerate these focused operations to meet the growing global cannabis demand, this partnership will enable us to strategically expand our current patent and IP portfolio in tandem. The team at Techson is the right partner for Bright Green and we look forward to this important collaboration.”

If you own or represent cannabis-related intellectual property that you would like Techson to review, please contact info (at) techsonip (dot) com.

About Techson IP
Founded in 2015 in Austin, Texas by IP attorneys, research experts and technologists, we are a patent and intellectual property strategy consulting firm with our experiential roots in patent transactions, patent research and building technology automation that provides us with a competitive advantage in IP.

Techson’s founders and executives have worked with and for the world’s largest patent owners and law firms. Techson’s researchers have conducted more than 20,000 research projects, and its 200+ clients include Fortune 500/Global 2000 corporations and Am Law 100 law firms. Its principals have also supported over $200 million in patent transactions and helped companies secure tens of millions in private equity and venture capital investments. Learn more visit or contact Techson at info (at) techsonip (dot) com.

About Bright Green
Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Its conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration gives Bright Green the opportunity to advance its vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit

Media Contact
BrightGreen (at) edelman (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Hochstatter
Follow >